𝔖 Bobbio Scriptorium
✦   LIBER   ✦

40 kDa peginterferon alfa-2A (PEGASYS®) in post-liver transplant recipients with established recurrent hepatitis C: preliminary results of a randomized multicenter trial: Peter Ferenci, Markus Peck-Radosavljevic, University of Vienna, Wien Austria; Wolfgang Vogel, Ivo Graziadei, Medical University, Innsbruck, Innsbruck Austria; Caroline Riely, University of Tennessee, Memphis, TN; Michael D Voigt, University of Iowa, Iowa City, IA; Ian M Marks, Richard Cambron, Lucy Wynohradnyk, S Chris Pappas, Roche Laboratories Inc, Nutley, NJ


Book ID
118689315
Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
189 KB
Volume
34
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.